Mitsui and ROHTO to jointly acquire Eu Yan Sang International

The acquisition is valued at approximately $593m.

Mitsui & Co., Ltd. has announced its joint decision with ROHTO Pharmaceutical Co., Ltd. to acquire Eu Yan Sang International Ltd (EYS), a traditional Chinese medicine manufacturer based in Singapore.

Under a conditional sale and purchase agreement (SPA), a special purpose company (SPC) jointly owned by Mitsui and ROHTO will acquire approximately 86% of EYS shares from Righteous Crane Holding Pte. Ltd.

The remaining 14% of EYS shares will be subject to a takeover bid upon fulfillment of conditions in the SPA. As part of management retention arrangements, the founding family of EYS will reinvest partially into the SPC.

The acquisition, valued at approximately $593m (S$800m), is targeted for completion by 30 June. 

Mitsui will hold about 30% of EYS shares whilst ROHTO will own approximately 60%, with the founding family retaining 10%.

EYS, established in 1879, operates over 170 retail outlets and 30 clinics across Singapore, Hong Kong, and Malaysia, offering integrative health and wellness solutions rooted in Traditional Chinese Medicine.

ALSO READ: Nearly 9 in 10 APAC consumers prioritise health and well-being

Mitsui's move aligns with its strategic focus on "Wellness Ecosystem Creation" and its aim to enhance health and well-being through preventive care solutions. 

ROHTO, meanwhile, aims to further expand and reinforce its core business activities in OTC pharmaceuticals, skincare products, and other food items.